1 min read
Add as a preferred source on Google

Celldex Shares Slip 2% After Barzolvolimab Misses Goals in Atopic Dermatitis Trial

A phase 2 atopic dermatitis study of barzolvolimab missed its primary and secondary endpoints. Celldex shares fell about 2% in after-hours trading Thursday, Nov. 19.

Celldex Therapeutics, Inc. (CLDX) shares fell about 2% in after-hours trading Thursday, Nov. 19, after a phase 2 atopic dermatitis study of barzolvolimab missed its primary and secondary endpoints.

The trial measured the percent change in weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) score.

The decline in after-hours trading was modest, at about 2%.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…